Reducing QT liability and proarrhythmic risk in drug discovery and development

British Journal of Pharmacology

Volumn 159, Issue 1, 2010, Pages 5-11

  Valentin, Jean Pierre ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Drug discovery and development; QT interval prolongation

Indexed keywords

PLACEBO;

CLINICAL RESEARCH; DRUG INDUCED DISEASE; DRUG INDUSTRY; DRUG SAFETY; DRUG SYNTHESIS; HEART PROARRHYTHMIA; HEART REPOLARIZATION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; POTASSIUM CURRENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; REVIEW; RISK FACTOR; TORSADE DES POINTES; UNITED KINGDOM;

ANIMALS; ARRHYTHMIAS, CARDIAC; DRUG DESIGN; DRUG DISCOVERY; HUMANS; LONG QT SYNDROME; PHARMACEUTICAL PREPARATIONS; TORSADES DE POINTES;

EID: 74549220695     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00547.x     Document Type: Review

References (29)

1. Abi-Gerges N, Valentin JP, Pollard CE (2010). Dog left ventricular midmyocardial myocytes for assessment of drug-induced delayed repolarization: short-term variability and proarrhythmic potential. Br J Pharmacol 159 : 77 92.
2. Anon 2000). ICHS7A: Safety Pharmacology Studies for Human Pharmaceuticals. CPMP/ICH/539/00. London, 16 November 2000. Available from: http://www.emea.europa.eu/pdfs/human/ich/053900en.pdf (accessed 29 October 2009).
3. Anon 2005a). ICH S7B: The Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization. CQT Interval Prolongation) by Human Pharmaceuticals. CPMP/ICH/423/02. London, 25 May 2005. Available from: http://www.emea.europa.eu/pdfs/human/ich/042302en.pdf (accessed 29 October 2009).
4. Anon 2005b). ICH E14: The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. CPMP/ICH/2/04. London, 25 May 2005. Available from: http://www.emea.europa.eu/ pdfs/human/ich/000204en.pdf (accessed 29 October 2009).
5. Darpo B (2010). The thorough QT study four years after the implementation of the ICH E14 guidance. Br J Pharmacol 159 : 49 57.
6. De Bruin ML, Pettersson M, Meyboom RH, Hoes AW, Leufkens HG (2005). Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. J Eur Heart 26 : 590 597.
7. Ducroq J, Moha H, Guilbot S, Dilly S, Laemmel E, Pons-Himbert C et al. (2010). Dextrazoxane protects the heart from acute doxorubicin-induced QT-prolongation: a key role for Iks. Br J Pharmacol 159 : 93 101.
8. Hanson LA, Bass AS, Gintant G, Mittelstadt S, Rampe D, Thomas K (2006). ILSI-HESI cardiovascular safety subcommittee initiative: evaluation of three non-clinical models of QT prolongation. J Pharmacol Toxicol Methods 54 : 116 129.
9. Hoffmann P, Warner B (2006). Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends. J Pharmacol Toxicol Methods 53 : 87 105.
10. Holbrook M, Malik M, Shah RR, Valentin J-P. (2009). Drug induced shortening of the QT/QTc interval: an emerging safety issue warranting further modeling and evaluation in drug research and development? J Pharmacol Toxicol Methods 59 : 21 28.
11. Malik M (2010) Facts, fancies, and follies of drug-induced QT/QTc interval shortening. Br J Pharmacol 159 : 70 76.
12. Omata T, Kasai C, Hashimoto M, Hombo T, Yamamoto K (2005). QT PRODACT: comparison of non-clinical studies for drug-induced delay in ventricular repolarization and their role in safety evaluation in humans. J Pharmacol Sci 99 : 531 541.
13. Männikkö R, Overend G, Perrey C, Gavaghan C, Valentin JP, Morten J et al. (2010). Pharmacological and electrophysiological characterization of nine, single nucleotide polymorphisms of the hERG-encoded potassium channel. Br J Pharmacol 159 : 102 114.
14. Park K (2008). Medical Research Council (MRC) Centre for Drug Safety Science. Available from: http://www.liv.ac.uk/research/environment/Drug-Safety- Centre.htm (accessed 29 October 2009).
15. Pettit SD, Berridge B, Sarazan RD (2009). A call for more integrated cardiovascular safety assessment. J Pharmacol Toxicol Methods Epub ahead of print] doi:10.1016/j.vascn.2009.08.001.
16. Piccini JP, Whellan DJ, Berridge BR, Finkle JK, Pettit SD, Stockbridge N et al. CSRC/HESI Writing Group 2009). Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the critical path initiative. Am Heart J 158 : 317 326.
17. Pollard CE, Abi-Gerges N, Bridgland-Taylor MH, Easter A, Harmer A, Hammond TG et al. (2010). Non-clinical strategies to address QT liability and proarrhythmic risk. Br J Pharmacol 159 : 12 21.
18. Pugsley MK, Authier S, Towart R, Gallacher DJ, Curtis MJ (2009). Beyond the safety assessment of drug-mediated changes in the QT interval... what' next? J Pharmacol Toxicol Methods 60 : 24 27.
19. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S et al. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58 : 32 45.
20. Salvi V, Karnad DR, Panicker GK, Kothari S (2010). Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development. Br J Pharmacol 159 : 34 48.
21. Shah RR (2005). Drugs, QT interval prolongation and ICH E14: the need to get it right. Drug Saf 28 : 115 125.
22. Shah RR (2010). Drug-induced QT interval shortening: potential implications and regulatory perspectives. Br J Pharmacol 159 : 58 69.
23. Stummann TC, Beilmann M, Duker G, Dumotier B, Fredriksson JM, Jones RL et al. (2009). Report and recommendations of the workshop of the European Centre for the Validation of Alternative Methods for Drug-induced Cardiotoxicity. Cardiovasc Toxicol 9 : 107 125.
24. Trepakova ES, Koerner J, Pettit SD, Valentin JP HESI Pro-Arrhythmia Committee (2009). A HESI consortium approach to assess the human predictive value of non-clinical repolarization assays. J Pharmacol Toxicol Methods 60 : 45 50.
25. Valentin JP (2002). Proceedings of the symposia on safety pharmacology, presented during the 3rd EPHAR meeting, Lyon, 6-9 July 2001. Fund Clin Pharmacol 16 : 73 74.
26. Valentin JP, Bialecki R, Ewart L, Hammond T, Leishmann D, Lindgren S et al. (2010). A framework to assess the translation of safety pharmacology data to humans. J Pharmacol Toxicol Methods 60 : 152 158.
27. Valentin JP, Pollard CE, Lainee P, Hammond T (2010). Value of non-clinical repolarization assays in supporting the discovery and development of safer medicines. Br J Pharmacol 159 : 25 33.
28. Wallis RM (2010). Integrated risk assessment and predictive value to humans of non-clinical repolarisation assays. Br J Pharmacol 159 : 115 121.
29. Webster R, Leishman D, Walker D (2002). Towards a drug concentration effect relationship for QT prolongation and torsades de pointes. Curr Opin Drug Discov Dev 5 : 116 126.